HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

αvβ3 Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo.

Abstract
Antibody-maytansinoid conjugates (AMCs) have emerged as one of the most promising active targeting cancer therapeutics. Their clinical use is, however, challenged by their low drug content, poor stability, high cost and potential immune response. Here, we designed and developed robust, cRGD-functionalized, reduction-sensitive polymeric micellar mertansine (DM1) prodrug (cRGD-MMP) that showed targeted treatment of B16F10 melanoma-bearing C57BL/6 mice. cRGD-MMP was obtained with a superb drug content of ~40wt.% and a small size of ~45nm from poly(ethylene glycol)-b-(poly(trimethylene carbonate)-graft-SSDM1) (PEG-P(TMC-g-SSDM1)) and cRGD-functionalized PEG-P(TMC-g-SSDM1) copolymers. cRGD-MMP exhibited excellent stability in 10% fetal bovine serum and cell culture medium while fast swelling and markedly accelerated drug release under a reductive environment. Confocal microscopy, flow cytometry and MTT assays indicated receptor-mediated uptake and high antitumor effect of cRGD-MMP in αvβ3 integrin over-expressing B16F10 melanoma cells. Notably, cRGD-MMP displayed a long elimination half-life of 5.25h and 4-fold better maximum-tolerated dose than free DM1. The in vivo studies demonstrated that cRGD-MMP effectively inhibited B16F10 melanoma growth and greatly improved mice survival rate as compared to free DM1 and non-targeted MMP control. cRGD-MMP with superior stability, drug loading, and αvβ3 targetability offers an attractive alternative to AMCs for malignant tumor therapy.
AuthorsPing Zhong, Hao Meng, Jie Qiu, Jian Zhang, Huanli Sun, Ru Cheng, Zhiyuan Zhong
JournalJournal of controlled release : official journal of the Controlled Release Society (J Control Release) Vol. 259 Pg. 176-186 (08 10 2017) ISSN: 1873-4995 [Electronic] Netherlands
PMID27986551 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2016 Elsevier B.V. All rights reserved.
Chemical References
  • Antineoplastic Agents, Phytogenic
  • Integrin alphaVbeta3
  • Micelles
  • Peptides, Cyclic
  • Polymers
  • Prodrugs
  • cyclic arginine-glycine-aspartic acid peptide
  • Maytansine
Topics
  • Animals
  • Antineoplastic Agents, Phytogenic (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Cell Line, Tumor
  • Drug Liberation
  • Drug Stability
  • Female
  • Integrin alphaVbeta3
  • Maytansine (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Melanoma, Experimental (drug therapy, pathology)
  • Mice, Inbred C57BL
  • Micelles
  • Peptides, Cyclic (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Polymers (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Prodrugs (administration & dosage, chemistry, pharmacokinetics, therapeutic use)
  • Tumor Burden (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: